H. Stewart Parker Joins Impel NeuroPharma's Board of Directors

H. Stewart Parker Joins Impel NeuroPharma's Board of Directors

Impel NeuroPharma is pleased to announce that H. Stewart Parker, a prominent leader in Seattle's Biotechnology community, has joined Impel's Board of Directors.

Most recently, Parker was the CEO of the Seattle-based Infection Disease Research Institute (IDRI), a nonprofit global health research institute developing diagnostics, vaccines, and treatments for neglected diseases. Parker started her career in biotech as the first employee of Immunex, growing with the company to become Vice President of Corporate Development.
 

Suggested Articles

In this week's EuroBiotech Report, AstraZeneca plans 2020 lupus filing, Roche's SMA trial hits endpoint and Kiadis cuts staff in R&D pivot.

In our EuroBiotech roundup this week, NEC and Vaximm ink cancer vaccine pact, Compugen posts cancer data and Lunac raises cash.

Biotech ATAI Life Sciences has partnered with artificial intelligence drug discovery specialist Cyclica to form a new JV.